

IntelGenx Technologies Corp.
Form 10QSB
November 14, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-QSB

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the Quarter September 30, 2007

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the transition period from _____ to _____

Commission File Number 000-31187

INTELGEX TECHNOLOGIES CORP.

(Exact name of small business issuer as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

87-0638336
(I.R.S. Employer Identification No.)

6425 Abrams, Ville Saint Laurent, Quebec H4S 1X9, Canada

(Address of principal executive offices)

(514) 331-7440

(Issuer's telephone number)

(Former Name, former Address, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

The number of shares outstanding of the issuer's common equity, as of the latest practicable date. (November 14, 2007) Class A 16,082,145

Check whether the issuer is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes No

Transitional Small Business Disclosure Format (Check one): Yes [] No [X]

IntelGenx Technologies Corp.

IntelGenx Technologies Corp.
Form 10-QSB

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	1
	Consolidated Balance Sheet	2
	Statement of Shareholders' Equity	3
	Statement of Operations and Comprehensive Loss	5
	Statement of Cash Flows	6
	Notes to Financial Statements	7
Item 2.	Management's Discussion and Analysis and Results of Operations	11
Item 3.	Controls and Procedures	17

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	18
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
Item 3.	Defaults upon Senior Securities	18
Item 4.	Submission of Matters to a Vote of Security Holders	18
Item 5.	Other Information	18
Item 6.	Exhibits	18
	Signatures	19

IntelGenx Technologies Corp.

Consolidated Interim Financial Statements

September 30, 2007
Expressed in U.S. Funds
(Unaudited)

Contents

IntelGenx Technologies Corp.

Consolidated Balance Sheet
 Expressed in U.S. Funds
 (Unaudited)

	September 30, 2007	December 31, 2006 (As adjusted) (Note 3)
Assets		
Current		
Cash and cash equivalents	\$ 910,062	\$ 227,578
Accounts receivable	231,336	135,223
Income taxes recoverable	10,989	9,380
Prepaid expenses	23,506	72,914
Investment tax credits receivable	141,876	43,880
	1,317,769	488,975
Property and Equipment	186,293	161,861
	\$ 1,504,062	\$ 650,836
Approved on Behalf of the Board		

Edgar Filing: IntelGenx Technologies Corp. - Form 10QSB

	September 30, 2007	December 31, 2006 (As adjusted) (Note 3)
Liabilities		
Current		
Accounts payable and accrued liabilities	165,086	129,994
Current maturity of long-term debt	-	24,026
	165,086	154,020
Loan Payable, Shareholder	100,837	86,076
Long-Term Debt	-	82,661
Convertible Notes , less unamortized discount and deferred charges of \$1,181,841 (note 5)	265,900	-
Future Income Tax Liability	354,219	-
Shareholders' Equity		
Capital Stock (note 6)	161	160
Additional Paid-in Capital (note 7)	2,097,890	1,165,403
Accumulated Deficit	(1,558,920)	(817,865)
Accumulated Other Comprehensive Income (Loss)	78,889	(19,619)
	618,020	328,079
	\$ 1,504,062	\$ 650,836

See accompanying notes

IntelGenx Technologies Corp.

Consolidated Statement of Shareholders' Equity
 For the Period Ended September 30, 2007
 Expressed in U.S. Funds
 (Unaudited)

	<u>Capital Stock</u>		Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total Shareholders' Equity
	Number	Amount				
Balance - December 31, 2006 (As adjusted, note 3)	16,007,489	\$ 160	\$ 1,165,403	\$ (19,619)	\$ (817,865)	\$ 328,079
Foreign currency translation adjustment for the period	-	-	-	98,508	-	98,508
Debenture conversion	74,656	1	52,258	-	-	52,259
Warrants issued	-	-	633,652	-	-	633,652
Stock-based compensation	-	-	195,635	-	-	195,635
Beneficial conversion feature	-	-	540,395	-	-	540,395
Transaction costs	-	-	(135,234)	-	-	(135,234)
Future income tax liability	-	-	(354,219)	-	-	(354,219)
Net loss for the period	-	-	-	-	(741,055)	(741,055)
Balance - September 30, 2007	16,082,145	\$ 161	\$ 2,097,890	\$ 78,889	\$ (1,558,920)	\$ 618,020
See accompanying notes						

IntelGenx Technologies Corp.

Consolidated Statement of Operations and Comprehensive Loss
Expressed in U.S. Funds
(Unaudited)

	For the Three-Month Period Ended September 30		For the Nine-Month Period Ended September 30	
	2007	2006	2007	2006
Revenue	\$ 178,735	\$ 17,298	\$ 602,113	\$ 205,984
Expenses				
Research and development	292,056	128,937	548,697	368,638
Research and development tax credits	(31,577)	(25,434)	(81,464)	(71,533)
Management salaries	150,692	80,100	217,683	110,254
General and administrative	52,161	21,656	115,030	61,235
Professional fees	75,678	47,492	293,481	54,136
Depreciation	12,659	9,339	30,411	26,904
Foreign exchange	407	55	(485)	897
Interest and financing fees	160,139	4,427	219,815	32,304
	712,215	266,572	1,343,168	582,835
Net Loss	(533,480)	(249,274)	(741,055)	(376,851)
Other Comprehensive Income (Loss)				
Foreign currency translation adjustment	65,368	(358)	98,508	(57)
Comprehensive Loss	\$ (468,112)	\$ (248,916)	\$ (642,547)	\$ (376,794)
Basic Weighted Average Number of Shares				
Outstanding	16,032,375	16,007,489	16,015,784	13,777,938
Basic and Diluted Loss Per Common Share (note 10)	\$ (0.03)	\$ (0.02)	\$ (0.05)	\$ (0.03)
See accompanying notes				

IntelGenx Technologies Corp.

Consolidated Statement of Cash Flows
Expressed in U.S. Funds
(Unaudited)

	For the Three-Month Period Ended September 30		For the Nine-Month Period Ended September 30	
	2007	2006	2007	2006
Funds Provided (Used) -				
Operating Activities				
Net loss	\$ (533,480)	\$ (249,274)	\$ (741,055)	\$ (376,851)
Depreciation	12,659	9,339	30,411	26,904
Financing fee paid in warrants	-	-	-	19,420
Investor relations services	2,793	33,312	67,314	33,312
Stock-based compensation	156,558	50,000	195,635	50,000
Interest accretion and amortization of debenture costs	78,746	-	95,664	-
	(282,724)	(156,623)	(352,031)	(247,215)
Changes in non-cash operating elements of working capital	(188,417)	111,844	(146,889)	(39,954)
	(471,141)	(44,779)	(498,920)	(287,169)
Financing Activities				
Long-term debt	-	24,460	-	53,754
Repayment of long-term debt	-	(10,876)	(107,871)	(16,724)
Loan payable, shareholder	-	(3,617)	-	-
Issue of capital stock	-	-	-	1,341,750
Transaction costs	-	(105,987)	(229,323)	(549,329)
Convertible notes	-	-	1,500,000	-
	-	(96,020)	1,162,806	829,451
Investing Activities				
Additions to property and equipment	(13,045)	644	(27,416)	(86,155)
Increase (Decrease) in Cash and Cash Equivalents	(484,186)	(140,155)	636,470	456,127
Effect of Foreign Exchange on Cash and Cash Equivalent	43,619	1,460	46,014	1,761
Cash and Cash Equivalents				
Beginning of Period	1,350,629	607,521	227,578	10,938
End of Period	\$ 910,062	\$ 468,826	\$ 910,062	\$ 468,826
See accompanying notes				

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
September 30, 2007
Expressed in U.S. Funds
(Unaudited)

1.

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and item 310(b) of Regulation S-B and are prepared using the same accounting policies as outlined in note 4 of IntelGenx Technologies Corp. financial statements for the year ended December 31, 2006 and 2005 except for those discussed in notes 3 and 4 below. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2007 are not necessarily indicative of the results that may be expected for the year ended December 31, 2007. The unaudited financial statements should be read in conjunction with the financial statements and notes thereto included in the IntelGenx Technologies Corp. audited financial statements for the years ended December 31, 2006 and 2005.

2.

Going Concern

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has reported an accumulated deficit of \$1,558,920 (2006 - \$817,865). To date, these losses have been financed principally through capital stock, long-term debt and debt from related parties. Additional capital and/or borrowings will be necessary in order for the Company to continue in existence and attaining profitable operations.

Management has continued to develop a strategic plan to build a management team, maintain reporting compliance and establish contracts with pharmaceutical companies. Management anticipates generating revenue through development contracts during the year. The Company has raised additional cash through the issuance of convertible debt in the nine month period ended September 30, 2007. Management is planning on raising additional fund in the future. Should the Company be unable to continue as a going concern, it may be unable to realize the carrying value of its assets and to meet its liabilities as they become due.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
September 30, 2007
Expressed in U.S. Funds
(Unaudited)

3.

Adjustment to Issued Financial Statements

Balance sheet as at December 31, 2006

The balance sheet as at December 31, 2006 has been adjusted, in this filing, to reflect the correction of an error in the previously issued financial statements. Capital stock was not disclosed at its par value with the excess of the proceeds in additional paid-in capital. As a result, capital stock is reduced by \$977,846 and additional paid-in capital is increased by the same amount. This error is not material to prior years audited statements since it is a reclassification within the stockholders equity section and has no impact on earnings or cash flows from operating or financing activities. The application of SAB 108 will allow a restatement of prior years financial statements when this year's 10-ksb is filed.

Balance sheet as at June 30, 2007

Following the release of the second quarter, errors in the interpretation of accounting standards relating to additional paid-in capital and convertible debt were identified. Transaction costs on the convertible notes were allocated between the convertible instrument, the detachable warrants and the beneficial conversion feature based on their relative fair value basis. As per EITF Issue 00-27, no transaction costs should be allocated to the non-detachable instruments such as the beneficial conversion features. The transaction costs recorded in additional paid-in capital are reduced by \$116,314 and those allocated to the convertible notes are increased by \$116,314. The future income tax liability relating to the temporary difference arising from the convertible notes with a beneficial conversion feature was not recorded as required under EITF Issue 05-8. As a result, a future tax liability of \$354,219 is set up and the additional paid-in capital is reduced by the same amount. The previously issued financial statements net earnings were not materially misstated as a result of the above errors. The only impact on the net earnings of the Consolidated Interim Financial Statements June 30, 2006 relate to the reclassification of transaction costs as discussed above and lead to an overstatement of interest accretion of \$4,545. Earnings for the three months ended September 30, 2007 have been presented taking account of this correction and earnings for the nine months ended September 30, 2007 are not affected. The remaining balance sheet reclassifications of the transaction costs and the future tax liabilities have no impact on earnings, earnings per share or cash flows from operations and therefore were considered immaterial in the prior quarter.

4.

Deferred Charges

Costs related to the issuance of the convertible notes have been offset against the convertible notes and are being amortized using the effective interest method over the term of the notes.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
 September 30, 2007
 Expressed in U.S. Funds
 (Unaudited)

5.

Convertible Notes

On May 22, 2007 the Company entered into convertible note agreements with certain institutional and accredited investors for amounts totalling \$1,500,000. The convertible notes bear interest at the rate of 8% per annum and are repayable on September 22, 2009. Interest is payable quarterly and payments commence on July 1, 2007. The notes are convertible into common stock of the Company, at the option of the holders, at a rate of \$0.70 per share. The Company also issued to the holders 2,142,857 stock purchase warrants exercisable at \$1.02 per share before May 22, 2012.

The Company may, at its option, elect to pay the interest by the issuance of shares of common stock. The number of shares is to be determined by dividing the amount of the interest payment by the number which is 85% of the average market price of the Company's common shares for the 20 trading days immediately prior to the interest payment date assuming the average market price is equal or greater than \$0.70 as adjusted for reverse and forward share split, recapitalizations and the like that occur after the date of the Securities Purchase Agreements.

In accordance with EITF Issue 98-5 "Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios", the Company recognized the value of the embedded beneficial conversion feature of \$540,395 as additional paid-in capital and an equivalent discount which will be expensed over the term of the convertible notes. In addition, in accordance with EITF Issue 00-27 "Application of Issue No.98-5 to Certain Convertible Instruments", the Company has allocated the proceeds of issuance between the convertible notes and the detachable warrants based on their relative fair value. Accordingly, the Company recognized the fair value of the detachable warrants of \$540,395 as additional paid-in capital and an equivalent discount against the convertible notes. The difference between the face amount of the convertible notes and their carrying value is amortized over the life of the convertible notes. The Black-Scholes Model was used to calculate the fair value of the warrants. The underlying assumptions included in the Black-Scholes Model were as follows:

Expected volatility	75%
Contractual life	5 years
Risk-free interest rate	4.39%
Dividend yield	Nil

Substantially all of the assets of the Company have been pledged as security of the convertible notes. As at September 30, 2007, \$43,000 of interest has been paid, and \$95,664 of interest has been accreted. In the months of August and September, 2007, \$52,259 of convertible notes were exchanged for 74,656 shares of common stock.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements
September 30, 2007
Expressed in U.S. Funds
(Unaudited)

6.

Capital Stock

	September 30, 2007	December 31, 2006
Authorized -		
100,000,000 common shares of \$0.00001 par value		
20,000,000 preferred shares		
Issued -		
16,082,145 (2006 - 16,007,489) common shares	\$ 161	\$ 160

On April 10, 2007, the Board of Directors of the Corporation approved an amendment, subject to shareholder approval, to the Corporation's Certificate of Incorporation, to increase the number of authorized common shares from 20,000,000 to 100,000,000 and to authorize the creation of 20,000,000 shares of "blank check" preferred shares. On April 10, 2007, the majority stockholder of the Corporation approved the same resolution as the Board of Directors. In the third quarter, 74,656 shares of common shares were issued as a result of the conversion of \$52,259 of convertible notes.

7.

Additional Paid-In Capital

Stock Options

On August 9, 2007, the Company granted 257,500 stock options to employees and directors to purchase common shares. The stock options are exercisable at \$1.15 per share and have a term of 10 years with vesting provisions ranging from immediate to vesting in equal increments over two years.

As at September 30, 2007, no stock options were exercised.

The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of \$178,577, using the following assumptions:

Expected volatility	71%
Expected life	5.00 - 5.75 years
Risk-free interest rate	4.58%
Dividend yield	Nil
Weighted average fair value of options at grant date	\$0.71

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements

September 30, 2007

Expressed in U.S. Funds

(Unaudited)

7.

Additional Paid-In Capital (Cont'd)

As a result of the grant, the Company recorded a compensation expense of \$85,221 in the nine-month period ended September 30, 2007. The Company also amortized \$110,414 in stock options granted in 2006 under the stock option plan. The Company has \$97,000 of stock option expense to be recorded in future periods.

Warrants

On May 22, 2007, IntelGenx Technologies Corp. issued 214,286 stock purchase warrants exercisable into common shares at \$0.70 per share which expire on May 22, 2011. As at September 30, 2007, no stock purchase warrants were exercised. The Stock purchase warrants were issued as part of the transaction costs in connection with the convertible notes described in note 5. The stock purchase warrants were accounted for at their fair value, as determined by the Black-Scholes valuation model, of \$93,257, using the assumptions below:

Expected volatility	75%
Expected life	4 years
Risk-free interest rate	4.39%
Dividend yield	Nil

8.

Income Taxes

On January 1, 2007, the Company adopted Financial Accounting Standards Board (FASB) Interpretation (FIN) No. 48, "Accounting for Uncertainty in Income Taxes - an Interpretation of FASB Statement No. 109" (FIN 48), which clarifies the accounting for uncertainty in tax positions. This Interpretation requires that the Company recognize in its financial statements, the impact of a tax position, if that position is more likely than not for being sustained on audit, based on the technical merits of the position. The adoption of FIN 48 did not have a material impact on our consolidated financial statements.

As of September 30, 2007, the federal and provincial income tax returns filed for the years 2003 to 2006 remain subject to examination by the taxation authorities.

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements

September 30, 2007

Expressed in U.S. Funds

(Unaudited)

9.

Related Party Transactions

During the nine month period ending September 30, 2007, the Company incurred expenses of approximately \$13,744 (2006 - \$13,602) for laboratory equipment leased from a shareholder and \$4,157 (2006 - \$4,305) for interest on the loan payable shareholder.

Included in professional fees are approximately \$18,104 (2006 - \$Nil) paid to a non-employee director of the Company.

In the first three quarters of 2007, the Company amortized interest and financing fees of approximately \$79,477 (2006 - \$Nil) for share-based compensation to a former officer and director of the Company in connection with the private placement closed on April 28, 2006.

Included in accounts payable and accrued liabilities is approximately \$7,800 (2006 - \$26,000) payable to shareholders.

The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed to by the related parties.

10. Basic and Diluted Loss Per Common Share

Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants, share-based compensation and convertible notes have been excluded from the calculation of diluted loss per share since they are anti-dilutive.

Edgar Filing: IntelGenx Technologies Corp. - Form 10QSB

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following information should be read in conjunction with the unaudited consolidated financial statements for the nine months period ended September 30, 2007 and 2006 and notes thereto. Unless otherwise indicated or the context otherwise requires, the "Company", "we", "us", and "our" refer to IntelGenx Technologies Corp. and its subsidiaries including IntelGenx Corp. ("IntelGenx")

Overview

Company Background

We are a drug delivery company established in 2003 and headquartered in Montreal, Quebec, Canada, which focuses on the development of novel oral immediate-release and controlled-release products for the generic pharmaceutical market. Our business strategy is to develop pharmaceutical products based on our proprietary drug delivery technologies and then license commercial rights for such products to pharmaceutical partners once the viability of a product has been demonstrated. We expect a partner company will, in some cases, fund development of the licensed products, complete the regulatory approval process with the U.S. Food and Drug Administration (FDA) or other regulatory agencies relating to the licensed products, and assume responsibility for marketing and distributing such products.

In addition, the Company anticipates that it may undertake full development of certain products without seeking a partner until the product reaches the marketing and distribution stage. The Company will assess the potential for successful development of a product and associated costs, and then determine at which stage it is most prudent to seek a partner, balancing such costs against the potential for additional returns earned by partnering later in the development process.

The Company has also undertaken a strategy under which it will work with pharmaceutical companies in order to develop new dosage forms in addition to already existing ones for pharmaceutical products for which patent protection is about to expire. Under §(505)(b)(2) of the Food, Drug, and Cosmetics Act, the FDA will grant a market exclusivity of up to three years for such a new dosage form. The Company anticipates significant returns from successfully obtaining market exclusivity in this manner.

The Company is currently continuing to develop the existing products in its pipeline and may also perform research and development on other potential products as the opportunities present themselves.

The Company does not currently plan to acquire a manufacturing facility. The Company currently purchases and/or leases, on an as-needed basis, the equipment necessary for performing research and development activities related to its products.

The Company will hire new personnel, primarily in the area of research and development, on an as-needed basis as the Company enters into partnership agreements and increases its research and development activities.

The IntelGenx Acquisition

On April 28, 2006, the Company entered into a Share Exchange Agreement, whereby the Company, (through its wholly-owned subsidiary 6544361 Canada, Inc., a Canadian company) acquired 100% of the issued and outstanding common stock and warrants of IntelGenx, (the "IntelGenx Acquisition"). Pursuant to the Share Exchange Agreement, and several separate related agreements, we issued, as consideration for the IntelGenx common stock, 14,507,489 shares of our common stock to various shareholders of IntelGenx along with 100,000 common stock purchase warrants to an IntelGenx shareholder. The warrants granted are exercisable at \$0.41 per share of common stock, and expire on April 28, 2008. The total shares of common stock issued by the Company pertaining to the IntelGenx Acquisition constituted 90.6 % of the 16,007,489 shares of our common stock then outstanding. Following the completion of the IntelGenx Acquisition, IntelGenx continued its operations as a subsidiary of the Company.

As part of the IntelGenx Acquisition, we issued a controlling amount of shares to the former IntelGenx shareholders who effectively gained controlling interest in the Company. According to US GAAP regulations, IntelGenx is deemed to be the accounting acquirer of the Company and the discussion of operations below relates to the operations of IntelGenx.

Currency rate fluctuations

The Company's operating currency is Canadian dollars while its reporting currency is U.S. dollars and, as such, the

Company's results of operations and balance sheet position have been affected by recent important currency rate fluctuations. The following management discussion and analysis takes this into consideration whenever significant.

Results of Operations nine months ended September 30, 2007 compared to the nine month period ended September 30, 2006.

	2007	2006	Increase/ (Decrease)	Percentage Change
Revenue	\$ 602,113	\$ 205,984	\$ 396,129	192%
Research and Development Expenses	548,697	368,638	180,059	49%
Research and Development Tax Credit	(81,464)	(71,533)	(9,931)	14%
Management salaries	217,683	110,254	107,429	97%
General and Administrative Expenses	115,030	61,235	53,795	88%
Professional Fees	293,481	54,136	239,345	442%
Interest and financing fees	219,815	32,304	187,511	580%
Net income (loss)	(741,055)	(376,851)	(364,204)	97%

Revenue

Our revenues from R&D services provided were \$580,091 and \$22,022 for interest for a total of \$602,113 for the nine month period ended September 30, 2007. This compares to \$205,984 for the same period in 2006 with no comparative interest revenue. We anticipate our revenue from development contracts in place at the time of filing of this report to

be approximately \$750,000 for the year 2007. We also expect revenue from additional research and development service contracts for which we are presently in discussions with potential clients. If we are successful in signing on potential clients, we would receive some additional upfront fees and research and development fees during the current year.

Research and development

Costs related to research and development increased to \$548,697 for the nine months ended September 30th compared to \$368,638 in 2006, which reflects the increased expenses due to the commencement of new development projects and the continuation of projects started in 2005 and 2006. Included in these costs are R&D Salaries of \$223,616 in 2007, \$14,900 of which are non-cash compensation. Since research and development expenses are directly related to the amount of R&D work performed, management expects a further increase of R&D expenses during the current year due to a further increase of development projects. For the nine months ended September 30, 2007, we have recorded estimated Research and Development Tax Credits and refunds of \$81,464 (\$71,533 in 2006).

Management Salaries and General and Administrative

Management salaries increased to \$217,683 for the nine month period ended September 30, 2007 (\$110,254 in 2006) while general and administrative expenses increased to \$115,003 (\$61,235 in 2006). Included in management salaries are \$85,220 in non cash compensation. The remaining cash increase in management salaries is attributable to the addition of the full time Chief Financial Officer and Vice-President Business Development. The increase in G&A expenses is attributed to the increase in corporate operations. Management expects general and administrative expenses from operations to increase according to an increase in operating activities.

Professional Fees

Professional fees increased to \$293,481 from \$54,136 for the same period in 2006, \$67,314 of which is non-cash compensation for Investor Relations contracts (\$33,312 in 2006). The increase reflects amounts paid to our legal counsel and auditors relating to our filing requirements in the U.S. and Canada.

Share-Based Compensation Expense, Warrants and Stock Based Payments

Share-based compensation expenses, warrants and share based payments totaled \$195,635 for the nine month period ended September 30, 2007 as compared to \$50,000 for the nine months ended September 30, 2006.

We expensed \$67,314 in stock based payments in consideration of investor relation services rendered during the nine months ended September 30, 2007. We also expensed \$84,741 in stock options granted to non-employee directors on August 9, 2007 (\$50,000 in 2006) and \$23,733 for options granted to company employees in 2006 and 2007 under the 2006 Stock Option Plan. In addition, \$10,570 was expensed for options granted for investor relation services. There remains approximately \$97,000 in stock based compensation to be expensed in fiscal 2007, 2008 and 2009 related to the issuance of options during 2006 and 2007. We anticipate issuance of additional options and warrants in the future, which will continue to result in stock-based compensation expense and may result in warrant amortization expense.

Financing Cost

We incurred interest and financing fee expenses of \$219,815 during the period ended September 30, 2007 compared to \$32,304 for the same period in 2006. Included in those expenses are non cash financing fees of \$76,591 (included in \$195,635 above) which we recorded for the amortization of 250,000 options issued to an officer of the company in connection with the IntelGenx Acquisition in April 2006. The options were granted under the 2006 Stock Option Plan.

Also included in the financing fee is interest on the convertible notes of approximately \$43,000. The remainder of \$10,085 interest expense relates to a long term debt which was paid off in May 2007 and interest paid on the shareholder loan. We expect to pay additional \$30,000 in interest on the convertible notes until the end of 2007.

Net Loss

We recorded a loss of \$741,055 in the period ended September 30, 2007 compared to a net loss of \$376,851 for the same period in 2006. Management believes that we will continue to operate at a net loss until such time as we can complete our business development efforts and begin to realize increased sales revenues.

Key items from the Balance Sheet September 30, 2007 compared to December 31, 2006.

	2007	2006	Increase/ (Decrease)	Percentage Change
Current Assets	\$ 1,317,769	\$ 488,975	\$ 828,794	169%
Property and Equipment	186,293	161,861	24,432	15%
Current Liabilities	165,086	154,020	11,066	7%
Loan Payable, Shareholder	100,837	86,076	14,761	17%
Long-term debt	-	82,661	(82,661)	100%
Convertible notes	265,900	-	265,900	N/A
Future Income Tax Liability	354,219	-	354,219	N/A
Capital Stock	161	160	1	1%
Additional Paid-in-Capital	2,097,890	1,165,403	932,487	80%
Current Assets				

At September 30, 2007 we had current assets of \$1,317,769 compared to \$488,975 at December 31, 2006. The net increase of \$828,794 is made up of increases in cash, accounts receivable, and income taxes and investment tax credits receivable of \$682,484, \$96,113, and \$99,605 respectively and a decrease in prepaid expenses of \$49,408.

Prepaid Expenses

At September 30, 2007 we had prepaid expenses of \$23,506 compared to \$72,914 at December 31, 2006. During the period we amortized 162,500 shares for investor relation services. This investor relation contract was acquired as a prepaid asset of \$133,250 at the time of the IntelGenx Acquisition in April 2006. The investor relations contract is now fully amortized.

Liquidity and Capital Resources

At September 30, 2007, we had cash and cash equivalents of \$910,062 (\$227,578 at December 31, 2006). We also had accounts receivable of \$231,336, and \$141,876 of investment tax credits receivable (\$135,223 and \$43,880 respectively at December 31, 2006).

At September 30, 2007, we had accounts payable and accrued liabilities of \$165,086. Professional fees represent \$74,067 of this amount while other accruals include \$7,782 due to a shareholder.

With the funds received as a result of the financing in May 2007, we are confident that we have sufficient cash available to satisfy our requirements. At September 30, 2007, we had total assets of \$1,504,062 and shareholders equity of \$618,020. (At December 31, 2006, \$650,836 and \$328,079 respectively)

Current Liabilities

At September 30, 2007 we had current liabilities of \$165,086 compared to \$154,020 at December 31, 2006. The net change of \$11,066 is made up of an increase of \$23,092 for accounts payable, approximately \$12,000 in currency exchange rate fluctuations on accounts payable, and a decrease in the current maturity of long-term debt of \$24,026. The long-term debt was reimbursed as a result of the Convertible Note Financing of May 22, 2007.

Property and Equipment

At September 30, 2007 we had property and equipment of \$186,293 compared to \$161,861 at December 31, 2006. The increase is made up of additions of \$14,924, \$6,227, and \$9,295 for laboratory, office, and computer equipment respectively, with \$30,411 for depreciation as well as a currency exchange rate fluctuation of \$24,397.

Loan Payable, Shareholder

At September 30, 2007 the loan payable, shareholder was \$100,837 compared to \$86,076 at December 31, 2006. The difference of \$14,761 reflects the currency exchange rate fluctuation.

Long term debt

At September 30, 2007 there was no long term debt as compared to \$82,661 at December 31, 2006. The long term debt was repaid subsequent to the issuance of the convertible note financing during the second Quarter of 2007.

Convertible Notes Financing

The Company completed on May 22, 2007, the sale of 8% Secured Convertible Notes in an aggregate principal amount of \$1,500,000 to certain institutional and accredited investors pursuant to a Securities Purchase Agreement. The Notes are convertible at any time into shares of the Company's common stock at a fixed conversion price of \$0.70. The investors shall have five years from May 22, 2007 to exercise 2,142,857 warrants. The warrants are exercisable on a one to one basis and the exercise price is \$1.02 per share. The Notes mature twenty-eight months from the date of issuance and they are secured by a lien on substantially all of the assets of the Company. The Company received net proceeds of approximately \$1.36 million.

In connection with the placement, the Company granted 214,857 warrants to the placement agent. The warrants are exercisable at \$0.70 per share and expire May 22, 2011.

At September 30, 2007 we had convertible notes of \$265,900 with no comparison at December 31, 2006. This represents \$1,500,000 in convertible note financing less unamortized discount and deferred charges of \$1,234,100. Notes in the amount of \$52,259 were converted into 74,656 shares of common stock during the third quarter.

Future Income Tax Liability

At September 30, 2007 we had a Future Income Tax Liability of \$354,219 with no comparable amount at December 31, 2006. This amount represents the tax liability relating to the temporary difference arising from the beneficial conversion feature attached to the convertible notes.

Capital Stock

At September 30, 2007 we had capital stock of \$161 compared to \$160 at December 31, 2006. A conversion of \$52,259 of convertible notes representing 74,656 shares of common stock occurred during the third quarter. Capital stock was disclosed at its par value with the excess of proceeds shown in Additional Paid-in-Capital.

Additional Paid-in-Capital

At September 30, 2007 we had additional paid-in capital of \$2,097,890 compared to \$1,165,403 at December 31, 2006. The change is made up of increases of \$52,258 for debenture conversion, \$633,652 and \$195,635 for the warrants and stock based compensation, and \$540,395 for the beneficial conversion feature associated with the convertible note financing. Also included are decreases of \$135,234 and \$354,219 for the transaction costs and future income tax liability associated with the convertible note financing.

Key items from the Statement of Cash Flows nine months ended September 30, 2007 compared to the nine month period ended September 30, 2006.

	2007	2006	Increase/ (Decrease)	Percentage Change
Operating Activities	\$ (498,920)	\$ (287,169)	\$ (211,751)	74%
Financing Activities	1,162,806	829,451	333,355	40%
Investing Activities	(27,416)	(86,155)	58,739	(68%)
Increase in cash and cash equivalent	636,470	456,127	180,343	39%
Cash and cash equivalent - end of period	910,062	468,826	441,236	94%
Statement of cash flows				

The net cash used in operating activities was \$498,920 for the nine months ended September 30, 2007 compared to a use of funds of \$287,169 for the same period in 2006. In 2007, the uses of cash include an operating loss of \$741,055 and a decrease in non-cash operating elements of working capital of \$146,889. The sources of cash include adding back non-cash items of \$30,411 for depreciation, \$67,314 for investor relation services, \$195,635 for share based compensation, and \$95,664 for interest and expense accretion related to the convertible notes.

The net cash provided by financing activities was \$1,162,806 for the nine months ended September 30, 2007 compared to a source of funds of \$829,451 for the same period in 2006. Of the net cash provided by financing activities in 2007, \$1,500,000 came from Debenture Financing, while funds were used to repay \$229,323 of related transaction costs and \$107,871 of the long-term debt.

The net cash used in investing activities was \$27,416 for the nine months ended September 30, 2007 compared to a use of funds of \$86,155 for the same period in 2006. The net cash of \$27,416 was used to purchase capital assets in 2007.

The overall change in cash and cash equivalents was an increase of \$636,470 versus an increase \$456,127 in 2006. The balance of cash at the end of the period was \$910,062 as compared to \$468,826 in 2006. The overall increase was mainly due to the issuance of convertible notes.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Forward-Looking and Cautionary Statements

This report contains certain forward-looking statements that involve risks and uncertainties relating to, among other things, our future financial performance or future events. Forward-looking statements give management's current expectations, plans, objectives, assumptions or forecasts of future events. All statements other than statements of current or historical fact contained in this Form 10QSB, including statements regarding our future financial position, business strategy, budgets, projected costs and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plans," "potential," "projects," "ongoing," "expects," "management believes," "we believe," "we intend," and similar expressions. These statements involve known and unknown risks, estimates, assumptions and uncertainties that could cause actual results to differ materially from the results set forth in this Annual Report. You should not place undue reliance on these forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements due to a number of factors such as: continued development of our technology; lack of product revenues successful completion of clinical trials and obtaining regulatory approval to market ability to protect our intellectual property dependence on collaborative partners ability to generate positive cash flow ability to raise additional capital if and when necessary dependence on key personnel; competitive factors; the operation of our business; and general economic conditions.

These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward looking statements. These forward-looking statements speak only as of the date on which they are made, and except to the extent required by federal securities laws, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Item 3. Controls and Procedures.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based upon that evaluation, our chief executive officer and principal financial officer concluded that our disclosure controls and procedures are effective to cause the material information required to be disclosed by us in the reports that we file or submit under the Exchange Act to be recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. There have been no significant changes in our internal controls or in other factors which could significantly affect internal controls subsequent to the date we carried out our evaluation.

PART II

Item 1. Legal Proceedings

There are no material pending legal proceedings to which we are a party or to which any of our property is subject and to the best of our knowledge, no such actions against us are contemplated or threatened.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

This Item is not applicable.

Item 3. Defaults Upon Senior Securities

This Item is not applicable.

Item 4. Submission of Matters to a Vote of Security Holders

At the Annual General Meeting on August 9, 2007 each of our Directors was re-elected by the Shareholders of the Corporation. The Shareholders also appointed RSM Richter as the Auditors of the Company for 2007.

Item 5. Other Information

This Item is not applicable.

Item 6. Exhibits

(a) Exhibits:

Exhibit 31.1 Certification of C.E.O. Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 31.2 Certification of Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 32.1 Certification of C.E.O. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 32.2 Certification of Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INTELGEX TECHNOLOGIES CORPORATION

Date: November 14, 2007

By: /S/ Horst Zerbe

Horst Zerbe
President, C.E.O. and
Director

Date: November 14, 2007

By: /S/ Gino Di Iorio

Gino Di Iorio
Chief Financial Officer
